SecBot SecBot
PRESS-RELEASE ·Filed Jun 29, 2026

ARQT

Arcutis Biotherapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This label expansion opens a new, underserved pediatric segment (ages 2-5) for ZORYVE, potentially driving incremental prescription volume and market share in pediatric psoriasis. Monitor upcoming quarterly earnings for commentary on pediatric adoption and any competitive responses from steroid-based alternatives. The approval also strengthens Arcutis' regulatory track record ahead of potential pipeline catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.22
T+0 close · Jun 29, 2026 · via day close
Latest settled
+0.61%
T+60 · $26.38
Vs SPY
−2.21%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 30 $26.22entry
  2. T+1 · 5mo ago −1.45%α −1.31% · $25.84
  3. T+5 · 4mo ago −0.57%α −1.18% · $26.07
  4. T+20 · 4mo ago +6.18%α +7.21% · $27.84
  5. T+60 · 8w ago +0.61%α −2.21% · $26.38
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream 0.3% for plaque psoriasis to children as young as 2 years old, the seventh FDA approval for ZORYVE in four years. This addresses a significant treatment gap in pediatric psoriasis, where limited steroid-free options existed for young children. The approval is based on a Phase 2 MUSE study and long-term extension data showing safety and efficacy consistent with adult/adolescent trials.

Key Facts

  • FDA approved sNDA for ZORYVE cream 0.3% to treat plaque psoriasis in children down to age 2, including intertriginous areas
  • Seventh FDA approval for ZORYVE in four years; first once-daily steroid-free topical approved for ages 2+ with plaque psoriasis
  • Approval based on 4-week MUSE study (ARQ-151-216) in children ages 2-5 and 24-week open-label extension (ARQ-151-306)
  • ZORYVE cream 0.3% already approved for adults and children down to age 6; this expansion adds ages 2-5
  • ZORYVE is the #1 prescribed branded topical therapy across atopic dermatitis, seborrheic dermatitis, and plaque psoriasis combined

Financial Impact

Expands addressable pediatric plaque psoriasis population by approximately 2-5 year age group; no specific revenue figures provided in release

revenuemarket share

Risk Factors

  • Competition from existing topical steroids and emerging non-steroidal therapies in pediatric psoriasis
  • Reimbursement and formulary access for the expanded pediatric indication may take time to materialize
  • Real-world adoption by pediatric dermatologists and primary care physicians may be slower than expected

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3319348

US Market Status

Market Closed · Opens in 9h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026